Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
4 hedge funds and large institutions have $154 invested in Titan Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 14 closing their positions.
1.67% less ownership
Funds ownership: 1.68% → 0.01% (-1.7%)
78% less funds holding
Funds holding: 18 → 4 (-14)
100% less capital invested
Capital invested by funds: $107K → $154 (-$107K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 14
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
-$102K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$2.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.25K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$91 |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$58 |
TTNP Hedge Fund Activity: Q4 2025 in Review
4 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q4 2025, worth a combined $154 — down 100% from $107K a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TTNP and 0 opened new positions — a net loss of 14 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was DRW Securities, exiting entirely with an estimated $102K sold.
- 4 institutional investors held Titan Pharmaceuticals (TTNP) as of Q4 2025, down from 18 in Q3 2025.
- Funds reported $154 of Titan Pharmaceuticals stock for Q4 2025, down 100% quarter-over-quarter.
- 0 funds opened new Titan Pharmaceuticals positions in Q4 2025 and 14 closed out, a net change of -14 holders.
- The largest Titan Pharmaceuticals seller in Q4 2025 was DRW Securities, an estimated $102K sold.
Based on aggregated 13F filings for Q4 2025.